ExpreS2ion Biotech Holding AB (DE:5JD0)

FRANKFURT:5JD0

5JD0

ExpreS2ion Biotech Holding AB

RESEARCH TOOLSreports

ExpreS2ion Biotech Holding AB (5JD0) Price & Analysis

Compare

2 Followers

5JD0 Stock Chart & Stats

€1.37

-€0.04(-2.01%)

At close: Jan 08 4:00 PM EST

€1.37

-€0.04(-2.01%)

Day’s Range― - ―

52-Week Range€0.30 - €2.47

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.50M

Enterprise Value-€33.16M

Total Cash (Recent Filing)€47.55M

Total Debt (Recent Filing)€2.21M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding3,530,233

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.27

Price to Sales (P/S)12.37

P/FCF Ratio-1.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.49

Revenue Forecast (FY)€923.72K

Bulls Say, Bears Say

Bulls Say

Proprietary Expression PlatformThe ExpreS2 proprietary insect-cell platform is a durable technical asset that enables production of complex antigens and VLP components. That capability creates a specialized service offering and a defendable competitive edge for recurring contract work and partner collaborations over the coming months.

Low Financial LeverageVery low debt levels provide structural financial flexibility: management can access capital or allocate existing cash to R&D and platform operations with lower near-term bankruptcy risk. This reduces fixed financing burden and supports execution while development outcomes materialize.

Diversified Commercialization PathsA dual revenue model—service contracts for protein production plus potential licensing/milestone streams—gives multiple durable monetization routes. Services can generate steady contract cashflows while partnerships offer step-change upside if programs progress or are out-licensed.

Bears Say

Persistent Cash BurnConsistently negative operating and free cash flow indicates the company consumes cash rather than self-funds growth. This structural cash burn raises ongoing external financing needs, increasing dilution risk or forcing spending cuts that could slow platform development and commercial expansion.

Small, Volatile And Declining RevenueSmall, inconsistent revenues limit the ability to cover fixed platform costs and achieve scale economics. Repeated declines undercut sustainable service cashflows and make it harder to convert the technological advantage into reliable, long-term cash generation without clear revenue stabilization or growth.

Structurally Loss-making And Shrinking Equity BasePersistent operating losses and a contracting equity base erode balance-sheet resilience over time. Negative returns on equity and declining assets restrict strategic options, increase vulnerability to funding shocks, and heighten the need for dilutive financing or asset sales to sustain operations.

5JD0 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was €0.30 and its highest was €2.47 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is €1.50M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 19, 2026 which is in 54 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -€0.223 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.223.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -€0.223 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.853%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in DE:5JD0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.